DYAI Stock Overview
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Dyadic International, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.49 |
| 52 Week High | US$2.40 |
| 52 Week Low | US$1.19 |
| Beta | 0.59 |
| 1 Month Change | -5.70% |
| 3 Month Change | 7.97% |
| 1 Year Change | -28.37% |
| 3 Year Change | -66.82% |
| 5 Year Change | -55.12% |
| Change since IPO | -76.16% |
Recent News & Updates
Recent updates
Is Dyadic International (NASDAQ:DYAI) In A Good Position To Deliver On Growth Plans?
Mar 14
Is Dyadic International (NASDAQ:DYAI) In A Good Position To Invest In Growth?
Oct 28Here's Why We're Watching Dyadic International's (NASDAQ:DYAI) Cash Burn Situation
Jun 21We're Hopeful That Dyadic International (NASDAQ:DYAI) Will Use Its Cash Wisely
Oct 05Dyadic collaborates with Syngene International to develop a COVID-19 vaccine candidate
May 26We're Not Very Worried About Dyadic International's (NASDAQ:DYAI) Cash Burn Rate
May 03Dyadic International's (NASDAQ:DYAI) Wonderful 318% Share Price Increase Shows How Capitalism Can Build Wealth
Feb 22Dyadic International (NASDAQ:DYAI) Is In A Good Position To Deliver On Growth Plans
Jan 18
Do Insiders Own Lots Of Shares In Dyadic International, Inc. (NASDAQ:DYAI)?
Dec 10Dyadic International reports Q3 results
Nov 12Shareholder Returns
| DYAI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.3% | 1.0% | 1.2% |
| 1Y | -28.4% | 0.7% | 24.9% |
Return vs Industry: DYAI underperformed the US Biotechs industry which returned 0.7% over the past year.
Return vs Market: DYAI underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| DYAI volatility | |
|---|---|
| DYAI Average Weekly Movement | 8.5% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: DYAI's share price has been volatile over the past 3 months.
Volatility Over Time: DYAI's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1979 | 7 | Mark Emalfarb | www.dyadic.com |
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform.
Dyadic International, Inc. Fundamentals Summary
| DYAI fundamental statistics | |
|---|---|
| Market cap | US$43.17m |
| Earnings (TTM) | -US$6.80m |
| Revenue (TTM) | US$2.90m |
14.9x
P/S Ratio-6.4x
P/E RatioIs DYAI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DYAI income statement (TTM) | |
|---|---|
| Revenue | US$2.90m |
| Cost of Revenue | US$1.98m |
| Gross Profit | US$922.96k |
| Other Expenses | US$7.72m |
| Earnings | -US$6.80m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.23 |
| Gross Margin | 31.84% |
| Net Profit Margin | -234.42% |
| Debt/Equity Ratio | 0% |
How did DYAI perform over the long term?
See historical performance and comparison